Literature DB >> 19003900

Molecular mechanisms of hepatocellular carcinoma.

Rajagopal N Aravalli1, Clifford J Steer, Erik N K Cressman.   

Abstract

Hepatocellular carcinoma (HCC) typically has poor prognosis, because it is often diagnosed at an advanced stage. Heterogeneous phenotypic and genetic traits of affected individuals and a wide range of risk factors have classified it a complex disease. HCC is not amenable to standard chemotherapy and is resistant to radiotherapy. In most cases, surgical resection and liver transplantation remain the only curative treatment options. Therefore, development of novel, effective therapies is of prime importance. Extensive research over the past decade has identified a number of molecular biomarkers as well as cellular networks and signaling pathways affected in liver cancer. Recent studies using a combination of "omics" technologies, microRNA studies, combinatorial chemistry, and bioinformatics are providing new insights into the gene expression and protein profiles during various stages of the disease. In this review, we discuss the contribution of these newer approaches toward an understanding of molecular mechanisms of HCC and for the development of novel cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003900     DOI: 10.1002/hep.22580

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  259 in total

1.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  A three-dimensional cell biology model of human hepatocellular carcinoma in vitro.

Authors:  Jianhua Tang; Jiefeng Cui; Rongxin Chen; Kun Guo; Xiaonan Kang; Yan Li; Dongmei Gao; Lu Sun; Changde Xu; Jie Chen; Zhaoyou Tang; Yinkun Liu
Journal:  Tumour Biol       Date:  2010-12-08

Review 3.  Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yihuan Luo; Fanghui Ren; Yongru Liu; Zhenhong Shi; Zhong Tan; Huojie Xiong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

5.  Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection.

Authors:  Haiou Liu; Weisi Liu; Zheng Liu; Yidong Liu; Weijuan Zhang; Le Xu; Jiejie Xu
Journal:  Tumour Biol       Date:  2015-02-27

Review 6.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

Review 7.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma.

Authors:  Ziqiang Li; Mei Tang; Bo Ling; Shiying Liu; Yu Zheng; Chunlai Nie; Zhu Yuan; Liangxue Zhou; Gang Guo; Aiping Tong; Yuquan Wei
Journal:  J Mol Med (Berl)       Date:  2013-11-27       Impact factor: 4.599

9.  MicroRNA-33a promotes cell proliferation and inhibits apoptosis by targeting PPARα in human hepatocellular carcinoma.

Authors:  Weiping Chang; Lei Zhang; Yao Xian; Zhaoxiang Yu
Journal:  Exp Ther Med       Date:  2017-03-20       Impact factor: 2.447

10.  Oncological and surgical results of laparoscopic versus open liver resection for HCC less than 5 cm: case-matched analysis.

Authors:  Sam-Youl Yoon; Ki-Hun Kim; Dong-Hwan Jung; Ami Yu; Sung-Gyu Lee
Journal:  Surg Endosc       Date:  2014-12-09       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.